Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679095 | 0.84 | ALDH1A1 (0.50) | RXRARXRBRXRGALDH1A1PTGS1 | |
| SCHEMBL5782136 | 0.84 | ALDH1A1 (0.58) | RXRARXRBRXRGALDH1A1PTGS1 | |
| SCHEMBL16956418 | 0.81 | CA1 (0.42) | ALDH1A1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL16952298 | 0.79 | RXRA (0.47) | RXRARXRBRXRGALDH1A1L3MBTL1 | |
| SCHEMBL12255396 | 0.77 | RXRA (0.43) | RXRARXRBRXRGALDH1A1PTGS1 | |
| SCHEMBL257565 | 0.77 | RXRA (0.43) | RXRARXRBRXRGALDH1A1PTGS1 | |
| SCHEMBL30181252 | 0.77 | RXRA (0.43) | RXRARXRBRXRGALDH1A1PTGS1 | |
| SCHEMBL2522090 | 0.77 | RXRA (0.43) | RXRARXRBRXRGALDH1A1PTGS1 | |
| SCHEMBL2809096 | 0.77 | ALDH1A1 (0.59) | ALDH1A1 | |
| SCHEMBL41250 | 0.77 | ALDH1A1 (0.69) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110577563-B | Fluorine-containing compound, preparation method thereof and application thereof in preparation of antitumor drugs | 山东师范大学 | 2020-09-04 | — | — | CN | claimed |
| CN-110577563-A | Fluorine-containing compound, preparation method thereof and application thereof in preparation of antitumor drugs | 山东师范大学 | 2019-12-17 | — | — | CN | claimed |
| US-9745288-B2 | Compounds and methods for treating cancer by inhibiting the urokinase receptor | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-08-29 | — | — | US | claimed |
| US-20150051247-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2015-02-19 | — | — | US | claimed |
| WO-2013025939-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2013-02-21 | — | — | WO | claimed |
| CN-117700456-A | Arylamine photocatalyst and preparation method thereof, defluorinated mono-bridged ring propeller compound, preparation method and application thereof | 国科大杭州高等研究院 | 2024-03-15 | — | — | CN | disclosed |
| CN-110577563-B | Fluorine-containing compound, preparation method thereof and application thereof in preparation of antitumor drugs | 山东师范大学 | 2020-09-04 | — | — | CN | disclosed |
| CN-110577563-A | Fluorine-containing compound, preparation method thereof and application thereof in preparation of antitumor drugs | 山东师范大学 | 2019-12-17 | — | — | CN | disclosed |
| US-9745288-B2 | Compounds and methods for treating cancer by inhibiting the urokinase receptor | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-20150051247-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2015-02-19 | — | — | US | disclosed |
| WO-2013025939-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051247-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR | PLAUR, PLAU, PLG | RXRA 1002/4885RXRB 820/4885RXRG 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.